On September 8, a group of more than 100 national and State-based advocacy group wrote to the House of representatives and the Senate Judiciary Committee, urged Congress to revise human resources 9 maintenance the Hatch Waxman Act protection, undermine the maintenance of patents for medical research.
In the letter, arguing that innovations are no threat to drug price competition and patent term Restoration Act (Hatch Waxman Act) and biological agents, price competition and innovation (BPCIA) in addition to the parties to review (IPR) during current violations.
According to this letter:
In addition to the parties to review (IPR) lawsuits aimed at more effective ways of dealing with patent challenges, but the abuse of intellectual property rights under the threat of drug price competition and patent term Restoration Act (commonly referred to as the Hatch Waxman Act) and biological agents, price competition and innovation (BPCIA) unique and specific mechanism to open the door. Congress established the uncompromising generic innovation patent dispute resolution framework to balance the interests of and generic manufacturers, and most important of all, individuals waiting for treatment or cure. This system is generally working well. Many generic drugs enter the market at the same time, innovative research and development to provide new treatments on patients. These trends are to help individuals with chronic illness and complex conditions of a longer, healthier life.
The letter states:
Congress never intended to damage intellectual property litigation in the Hatch-Waxman patent dispute resolution framework and BPCIA. We urge Congress to retain the hatch gaiweikesiman and BPCIA to avoid weakening the maintenance of medical research’s patented design is a detailed and complex system for big brother 9 includes language. Strong patent will ensure that innovative ideas from the lab to the people who need them most.
See the entire letter.